Equity Overview
Price & Market Data
Price: $0.409
Daily Change: -$0.011 / 2.69%
Range: $0.395 - $0.441
Market Cap: $10,706,107
Volume: 300,659
Performance Metrics
1 Week: -12.81%
1 Month: -25.19%
3 Months: -31.83%
6 Months: -36.30%
1 Year: -87.97%
YTD: -43.98%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.